Profile data is unavailable for this security.
About the company
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.
- Revenue in USD (TTM)758.90k
- Net income in USD-45.68m
- Incorporated2018
- Employees12.00
- LocationOnconetix Inc201 E. Fifth Street, Suite 1900CINCINNATI 45202United StatesUSA
- Phone+1 (513) 620-4101
- Fax+1 (845) 818-3588
- Websitehttps://onconetix.gcs-web.com/
Mergers & acquisitions
Acquired company | ONCO:NAQ since announced | Transaction value |
---|---|---|
ProteoMediX Ltd | -35.75% | -- |
Wraser LLC | -80.48% | 3.50m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revelation Biosciences Inc | 0.00 | -8.96m | 3.61m | 9.00 | -- | 0.381 | -- | -- | -32.09 | -32.09 | 0.00 | 5.80 | 0.00 | -- | -- | 0.00 | -54.61 | -- | -91.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
Mosaic Immunoengineering Inc | 0.00 | -897.69k | 3.62m | 3.00 | -- | -- | -- | -- | -0.1245 | -0.1245 | 0.00 | -0.8498 | 0.00 | -- | -- | 0.00 | -789.46 | -- | -- | -- | -- | -- | -- | -- | -- | -26.91 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
Sentient Brands Holdings Inc | 0.00 | -818.63k | 3.86m | 2.00 | -- | -- | -- | -- | -0.0145 | -0.0145 | 0.00 | -0.036 | 0.00 | 0.0188 | -- | 0.00 | -317.87 | -220.36 | -- | -- | -- | 41.81 | -- | -31,451.19 | 0.0354 | -2.27 | -- | -- | -73.68 | -- | 34.98 | -- | -- | -- |
Zyversa Therapeutics Inc | 0.00 | -105.53m | 3.97m | 7.00 | -- | 0.3534 | -- | -- | -1,791.54 | -1,791.54 | 0.00 | 13.44 | 0.00 | -- | -- | 0.00 | -142.87 | -- | -164.77 | -- | -- | -- | -- | -- | -- | -17,576.86 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
Onconetix Inc | 758.90k | -45.68m | 3.98m | 12.00 | -- | -- | -- | 5.24 | -2.41 | -2.41 | 0.0407 | 1.91 | 0.0156 | -- | 4.70 | 63,241.67 | -93.67 | -- | -137.89 | -- | -123.62 | -- | -6,019.45 | -- | 0.2752 | -17.12 | 0.2352 | -- | -- | -- | -176.78 | -- | -- | -- |
GB Sciences Inc | 0.00 | -4.03m | 3.98m | 3.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0119 | 0.00 | -- | -- | 0.00 | -255.86 | -49.16 | -- | -131.40 | -- | 6.03 | -- | -995.19 | -- | -8.63 | -- | -- | -- | -- | -2,715.25 | -- | -60.82 | -- |
Tharimmune Inc | 0.00 | -8.89m | 4.02m | 2.00 | -- | 0.5698 | -- | -- | -111.65 | -111.65 | 0.00 | 8.97 | 0.00 | -- | -- | 0.00 | -130.60 | -- | -173.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
NS Wind Down Co Inc | 162.47m | -166.43m | 4.09m | 703.00 | -- | -- | -- | 0.0252 | -3.53 | -3.53 | 3.44 | -1.05 | 0.4936 | 2.07 | 4.30 | 231,113.80 | -50.56 | -30.01 | -62.82 | -34.66 | 35.72 | 57.14 | -102.44 | -80.87 | 2.02 | -70.17 | 1.29 | -- | -12.28 | 2.06 | -38.43 | -- | 40.03 | -- |
Phio Pharmaceuticals Corp | 0.00 | -9.38m | 4.09m | 8.00 | -- | 0.6145 | -- | -- | -3.71 | -3.71 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -113.26 | -71.92 | -145.23 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
Exicure Inc | 21.77m | 2.97m | 4.10m | 6.00 | 0.2769 | 0.9106 | 1.06 | 0.1881 | 1.71 | 1.71 | 3.07 | 0.52 | 1.04 | -- | -- | 1,674,923.00 | 14.17 | -41.75 | 42.53 | -55.57 | -- | -- | 13.64 | -302.07 | -- | -- | 0.00 | -- | 6,068.12 | 24.29 | 95.97 | -- | -59.57 | -- |
Ensysce Biosciences Inc | 1.75m | -11.55m | 4.15m | 7.00 | -- | 1.07 | -- | 2.37 | -3.74 | -3.74 | 0.5109 | 0.5115 | 0.3886 | -- | 9.06 | 249,514.30 | -257.00 | -17.68 | -574.02 | -19.42 | -- | -- | -661.34 | -715.78 | -- | -6.25 | 0.0671 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
60 Degrees Pharmaceuticals Inc | 378.20k | -1.07m | 4.21m | 2.00 | -- | -- | -- | 11.13 | -0.1563 | -0.1563 | 0.0564 | 0.6121 | 0.0474 | 0.8827 | 1.90 | 126,066.70 | -9.87 | -- | -- | -- | -23.45 | -- | -208.43 | -- | 6.77 | -- | 0.0217 | -- | -50.40 | -- | 35.51 | -- | -- | -- |
Alzamend Neuro Inc | 0.00 | -12.40m | 4.28m | 4.00 | -- | -- | -- | -- | -1.87 | -1.87 | 0.00 | -0.572 | 0.00 | -- | -- | 0.00 | -267.15 | -- | -880.90 | -- | -- | -- | -- | -- | -- | -1,352.90 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
Geovax Labs Inc | 0.00 | -27.78m | 4.35m | 17.00 | -- | 73.14 | -- | -- | -14.42 | -14.42 | 0.00 | 0.0235 | 0.00 | -- | -- | 0.00 | -180.60 | -108.34 | -242.41 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
Neximmune Inc | 0.00 | -25.86m | 4.39m | 6.00 | -- | 1.60 | -- | -- | -24.16 | -24.16 | 0.00 | 2.16 | 0.00 | -- | -- | 0.00 | -130.41 | -115.07 | -183.16 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
Holder | Shares | % Held |
---|---|---|
American Money Management Corp.as of 31 Mar 2024 | 1.44m | 6.45% |
Cetera Investment Advisers LLCas of 31 Mar 2024 | 320.00k | 1.43% |
Bank of America, NA (Private Banking)as of 31 Mar 2024 | 125.00k | 0.56% |
Two Sigma Securities LLCas of 31 Mar 2024 | 113.43k | 0.51% |
Fifth Third Bank, NA (Investment Management)as of 31 Mar 2024 | 96.20k | 0.43% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 73.51k | 0.33% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 53.56k | 0.24% |
Geode Capital Management LLCas of 31 Mar 2024 | 53.11k | 0.24% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 38.29k | 0.17% |
Bahl & Gaynor, Inc.as of 31 Mar 2024 | 34.71k | 0.16% |